It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Acute lymphoblastic leukemia (ALL) is the most frequent malignancy in children. With the use of more modern, efficient treatments, 5-year survival has reached more than 90% in this population. However, this achievement comes with many secondary and long-term effects since more than 65% of the survivors experience at least one severe complication, including the metabolic syndrome and cardiovascular diseases. The main objective of the present work was to characterize the composition of HDL particles isolated from pediatric ALL survivors. HDLs from 8 metabolically healthy ALL survivors, 8 metabolically unhealthy ALL survivors and 8 age- and gender-matched controls were analyzed. The HDL fraction from the survivors contained less cholesterol than the controls. In addition, proteomic analyses revealed an enrichment of pro-thrombotic (e.g., fibrinogen) and pro-inflammatory (e.g., amyloid A) proteins in the HDLs deriving from metabolically unhealthy survivors. These results indicate an alteration in the composition of lipid and protein content of HDL from childhood ALL survivors with metabolic disorders. Although more work is needed to validate the functionality of these HDLs, the data seem relevant for survivor health given the detection of potential biomarkers related to HDL metabolism and functionality in cancer.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Sainte-Justine University Hospital Health Center, Université de Montréal, Montreal, Research Centre, Quebec, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Montreal, Department of Nutrition, Quebec, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
2 Université de Montréal, Institute of Research in Immunology and Cancer, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
3 Sainte-Justine University Hospital Health Center, Université de Montréal, Montreal, Research Centre, Quebec, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
4 Université de Montréal, Montreal, Department of Pediatrics, Quebec, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
5 Sainte-Justine University Hospital Health Center, Université de Montréal, Montreal, Research Centre, Quebec, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357); Université de Montréal, Montreal, Department of Pediatrics, Quebec, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)